Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In relation to the lipodystrophy syndrome, it appears that the most powerful determinant of subcutaneous fat wasting is an interaction between these two drug classes. In this review, possible mechanisms underlying the contributions of both PI and NRTI drugs are reviewed, with an emphasis on their effects on adipose tissue. On this basis, an ‘adipocentric’, or minimal model of the syndrome is developed, in which divergent effects at the adipocyte of NRTIs (mitochondrial toxicity) and PIs (insulin resistance and impaired adipocyte maturation) interact to produce a phenotype that is consistent with clinical observations.
References
1.
JohnM., NolanD., & MallalS.Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Therapy2001; 6: 9–20.
PoloR., VerdejoJ., Martinez-RodriguezS., MadrigalP., & Gonzalez-MunozM.Lipopatrophy, fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes2000; 25: 284–285.
4.
MallalS.A., JohnM., MooreC.B., JamesI.R., & McKinnonE.J.Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS2000; 14: 1309–1316.
5.
PurnellJ.Q., ZambonA., KnoppR.H., PizzutiD.J., AchariR., & LeonardJ.M.Effect of ritonavir on lipids and post-heparin lipase in normal subjects. AIDS2000; 14: 51–57.
6.
NoorM.A., LoJ.C., MulliganK., SchwarzJ.M., HalvorsenR.A., SchambelanM.Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS2001; 15: 11–18.
7.
MulliganK., Grunfeld, TaiV.W., AlgrenH., PangM., ChernoffD.N., LoJ.C., & SchambelanM.Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of change in body composition in patients with HIV infection. Journal of Acquired Immune Deficiency Syndromes2000; 23: 35–43.
8.
WankeC., GerriorJ., SkinnerS., McNamaraJ.R., & SchaeferE.J.Lipid profiles in HIV-infected patients before and after protease inhibitor therapy.2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto Canada, 13–15 September 2000, Abstract P8.
9.
Saint-MarcT., PartisaniM., Poizot-MartinI.Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS2000; 14: 37–49.
10.
TsiodrasS., MantzorosC., HammerS., & SamoreM.Effects of protease inhibitors on hyperglyceamia, hyperlipidaemia, and lipodystrophy. A 5-year cohort study. Archives of Internal Medicine2000; 160: 2050–2056.
11.
ThiebautR., DabisF., MalvyD., Jaqmin-GaddaH., MercieP., & DaucourtV.Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine cohort, France, 1996 to 1998. Journal of Acquired Immune Deficiency Syndromes2000; 23: 261–265.
12.
LawM., EmeryS., FrenchM., CarrA., ChuahJ., & CooperD.Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomised controlled studies of combination antiretroviral therapy.2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada, 13–15 September 2000, Abstract 028.
13.
JolyV., FlandreP., MeiffredyV., HazebrouckS., HarelM., AboulkerJ.P., & YeniP.Assessment of lipodystrophy in patients previously exposed to AZT, ddI or ddC, but naïve for d4T and protease inhibitors (PI), and randomised between d4T/3TC/Indinavir and AZT/3TC/Indinavir (NOVAVIR trial).8th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill, USA, 4–8 February 2001, Abstract 539.
14.
MolinaJ.M., AngeliniE., CotteL.Prevalence of lipodystrophy in long term follow up of a clinical trial comparing various combinations of nucleoside analogue reverse transcriptase inhibitors (NRTI), ALBI trial:ANRS 070.7th Conference on Retroviruses and Opportunistic Infections. San Francisco, Calif., USA, 30 January –February 2 2000, Abstract 19.
15.
Van der WalkM., GisolfE.H., ReissP., WitFWNM, JapourA., WeverlingG.J.Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS2001; 15: 847–855.
16.
GisolfE.H., JurriaansS., PelgromJ., van WanzeeleF., van der EndeM.E., BrinkmanK.(Prometheus Study Group). The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. AIDS2000; 14: 405–413.
17.
CohenC., CameronW., XuY., RodeR., MellorsJ., FarthingC., PoretzD., MarkovitzD., HoD., McMahonD., DrennonD., SelnessK., RyanJ., SunE., & JapourA.J.Effect of NRTI intensification on prevalence of body composition abnormalities at week 144 of ritonavir plus saquinavir therapy in an HIV-infected cohort.2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada, 13–15 September 2000, Abstract P56.
18.
CameronD.W., JapourA.J., XuY., HsuA., MellorsJ., FarthingC.Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS1998; 13: 213–224.
19.
PoloR., VerdejoJ., Martinez-RodriguezS., MadrigalP., & Gonzalez-MunozM.Lipodystrophy in protease-inhibitor-naive HIV-infected patients.40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17–20 September 2000, Abstract 1282.
20.
MillerK.D., JonesE., YanovskiJ.A., ShankarR., FeuersteinI., & FalloonJ.Visceral abdominal-fat accumulation associated with use of indinavir. Lancet1998; 351: 871–875.
21.
GalliM., RidolfoA.L., GervasoniC., SantambrogioS., RavasioL., CorsicoL.Risk of developing metabolic alterations in PI-naive HIV-1 infected patients treated with RTI.40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17–20 September 2000, Abstract 1292.
22.
WitFWNM, GisolfE.H., OostwegelL.M.M., WeverlingG.J., LangeJ.M.A., ReissP.Stavudine use is not associated with an incremental risk of hyperlipidaemia during treatment with HIV-1 protease inhibitors.1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, Calif. USA, 26–28 June 1999, Abstract O65.
23.
HadiganC., MeigsJ.B., CorcoranC., RietschelP., PiecuchS., BasgozN.Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clinical Infectious Diseases2001; 32: 130–139.
24.
WareL.J., MorleseJ., BurdgeG., JacksonA.A., GazzardB., & WoottonS.A.Differences in postprandial lipid metabolism in patients with PI-associated and NRTI-associated lipodystrophy.2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada, 13–15 September 2000, Abstract O20.
25.
PaulikM., LancasterM., CroomD., SpencerD., WeielJ., LenhardJ.Anti-oxidants rescue NRTI-induced metabolic changes in AKR/J mice.2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada, 13–15 September 2000, Abstract O8.
26.
IsolaL.M., ZhouS-L, KiangC-L, StumpD.D., BradburyM.W., & BerkP.D.3T3 fibroblasts transfected with a cDNA for mitochondrial aspartate aminotransferase express plasma membrane fatty acid-binding protein and saturable fatty acid uptake. Proceedings of the National Academy of Sciences, USA1995; 92: 9866–9870.
27.
BradburyM.W., & BerkP.D.Mitochondrial aspartate amino-transferase: direction of a single protein with to distinct functions to two subcellular sites does not require alternative splicing of the mRNA. The Biochemical Journal2000; 348: 423–427.
28.
LongleyM.J., RoppP.A., LimS.E., & CopelandW.C.Characterization of the native and recombinant catalytic subunit of human DNA polymerase γ: Identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity. Biochemistry1998; 37: 10529–10539.
29.
BrinkmanK., SmetinkJ.A., RomjinJ.A., & ReissP.Mitochondrial toxicity induced by nucleoside analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet1999; 354: 1112–1115.
30.
KakudaT.N.Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clinical Therapeutics2000; 22: 685–708.
31.
WhiteA.J.Mitochondrial toxicity and HIV therapy. Sexually Transmitted Infections2001; 77: 158–173.
32.
MartinJ.L., BrownC.E., Matthews-DavisN., & ReardonJ.E.Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrobial Agents & Chemotherapy1994; 38: 2743–2749.
33.
DolceV., FiermonteG., RunswickM.J., PalmieriF., & WalkerJ.E.The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proceedings of the National Academy of Sciences, USA2001; 98: 2284–2288.
34.
DudleyM.N.Clinical pharmacokinetics of nucleoside anti-retroviral agents. Journal of Infectious Diseases1995; 171(Suppl. 2): S99–S112.
35.
SomadossiJ-P. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2′-3′-dideoxynucleoside analogues. Journal of Infectious Diseases1995; 171(Suppl. 2): S88–S92.
36.
WangL., Munch-PetersenB., SjobergA.H., HellmanU., BergmanT., JornvallH., & ErikssonS.Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Letters1999; 443: 170–174.
37.
RampazzoC., GallinaroL., MilanesiE., FrigimelicaE., ReichardP., & BianchiV.A deoxyribonucleotidase in mitochondria: Involvement in regulation of dNTP pools and possible link to genetic disease. Proceedings of the National Academy of Sciences, USA2000; 97: 8239–8244.
38.
LavieA., OstermannN., BrundiersR., GoodyR.S., ReinsteinJ., KonradM., & SchlichtingI.Structural basis for efficient phosphorylation of 3′-azidothymidine monophosphate by Escherichia coli thymidylate kinase. Proceedings of the National Academy of Sciences, USA1998; 95: 14045–14050.
39.
ArnerE.S.J., SpasokoukotskajaT., & ErikksonS.Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochemical and Biophysical Research Communications1992; 188: 712–718.
40.
WangJ., SuC., NeuhardJ., & ErikssonS.Expression of human mitochondrial thymidine kinase in Escherichia coli: correlation between the enzymatic activity of pyrimidine nucleoside analogues and their inhibitory effect on bacterial growth. Biochemical Pharmacology2000; 59: 1583–1588.
41.
TurrizianiO.Simeoni E, Dianzani F & Antonelli G. Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line. Antiviral Therapy1998; 3: 191–194.
42.
CuiL., LocatelliL., XieM-Y, & SommadossiJ-PEffect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. The Journal of Pharmacology and Experimental Therapeutics1997; 280: 1228–1234.
43.
JohanssonM., KarlssonA.Cloning and expression of human deoxyguanosine kinase cDNA. Proceedings of the National Academy of Sciences, USA1996; 93: 7258–7262.
44.
WalkerU.A., BickelM., Lutke VolksbeckS.I., SchoferH., SetzerB., RickertsV.Decrease of mitochondrial DNA content in adipose tissue of HIV-1-infected patients treated with NRTIs. Antiviral Therapy2000; 5 (Suppl. 5): 5.
45.
ShikumaC., HuN., MilneC., YostF., ShimizuS., ShiramizuB.Analysis of subcutaneous adipose tissue mitochondrial DNA from individuals with HAART-associated lipodystrophy.8th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., USA, 4–8 February 2001, Abstract 665.
46.
MallalS.A., HammondE.L., MartinA., TaylorL., JohnM., & NolanD.A.Mitochondrial DNA depletion, assessed by real-time PCR-based quantitative assay, in subcutaneous fat of HIV-infected patients: evidence for a role in the etiology of fat wasting.4th International Conference on Nutrition and HIV Infection. Cannes, France, 19–21 April 2001, Abstract O7.
47.
MallalS., NolanD., JohnM., ChongD., MetcalfC., & LathamB.Light and electron microscopy findings in subcutaneous fat in antiretroviral treated and HIV-infected patients.XIII International AIDS Conference. Durban, South Africa 2000, Abstract LpPeB7054.
48.
LloretaJ., DomingoP., PujolR., ArroyoJ., SambeatM., & SerranoS.An ultrastructural insight into the pathogenesis study of HAART-associated partial lipodystrophy.1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, 8–11 July 2001, Abstract 494.
49.
ChowC.W., & ThorburnD.R.Morphologic correlates of mitochondrial dysfunction in children. Human Reproduction2000; 15 (Suppl. 2): 68–78.
50.
LinnaneA.W., Degli EspostiM., GenerowiczM., LuffA.R., & NagleyP.The universality of bioenergetic disease and amelioration with redox therapy. Biochimica et Biophysica Acta1995; 127: 191–194.
51.
FraynK.N.Metabolism regulation. A human perspective.1996; pp 72–80. London, UK: Portland Press.
52.
KangJ., HeartE., & SungC.K.Effects of cellular ATP depletion on glucose transport and insulin signalling in 3T3-L1 adipocytes. American Journal of Physiology Endocrinology and Metabolism2001; 280: E428–E435.
53.
RossmeislM., SyrovyI., BaumurkF., FlachsP., JanovskaP., & KopeckyJ.Decreased fatty acid synthesis due to mitochondrial uncoupling in adipose tissue. FASEB Journal2000; 14: 1793–1800.
54.
WinderW., HardieD.G.AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes. American Journal of Physiology1999; 277: E1–E10.
55.
RudermanN.B., SahaA.K., VavvasD., & WittersL.A.Malonyl-CoA, fuel sensing, and insulin resistance. American Journal of Physiology1999; 276: E1–E18.
56.
HardieD.G., CarlingD., & CarlsonM.The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell. Annual Review of Biochemistry1998; 67: 821–855.
57.
SullivanJ.E., BrocklehurstK.J., MarleyA.E., CareyF., CarlingD., & BeriR.K.Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Letters1994; 353: 33–36.
58.
SoltysB.J., & GuptaR.S.Mitochondrial proteins at unexpected locations: export of proteins from mitochondria from an evolutionary perspective. International Review of Cytology1999; 194: 133–196.
59.
ZhouS-L, StumpD., KiangC-L, IsolaL.M., & BerkP.D.Mitochondrial aspartate aminotransferase expressed on the surface of 3T3-L1 adipocytes mediates saturable fatty acid uptake. Proceeding of the Society for Experimental Biology and Medicine1995; 208: 263–270.
60.
HertzelA.V., & BernlohrD.A.Regulation of adipocyte gene expression by polyunsaturated fatty acids. Molecular and Cellular Biochemistry1998; 188: 33–39.
61.
ShenW-J, SridharK., BernlohrD.A., & KraemerF.B.Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proceedings of the National Academy of Sciences, USA1999; 96: 5528–5532.
62.
CoeN.R., SimpsonM.A., & BernlohrD.A.Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. Journal of Lipid Research1999; 40: 967–972.
63.
ChristeffN., MelchiorJ-C, de TruchisP., PerronneC., NunezE.A., & GougeonM-LLipodystrophy defined by a clinical score in HIV-infected men on highly active anti-retroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS1999; 13: 2251–2260.
64.
VigourouxC., GharakanianS., SalhiY., NguyenT-H, ChevenneD., CapeauJ.Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metabolism1999; 25: 225–232.
65.
BonnetE., RuidavetsJ-B, TuechJ., FerrieresJ., ColletX., FauvelJ.Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. Journal of Clinical Endocrinology and Metabolism2001; 86: 296–302.
66.
BehrensG., DejamA., SchmidtH., BalksH-J, BrabantG., KornerT.Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS1999; 13: F63–F70.
67.
BertholdH.K., ParhoferK.G., RitterM.M., AddoM., WasmuthJ.C., SchlieferK.Influence of protease inhibitor therapy on lipoprotein metabolism. Journal of Internal Medicine1999; 246: 567–575.
SekharR.V., WhiteA.C.Jr., JahoorF., VisnegarwalaF., ReedsP.J., & BalasubramanyamB.HIV-associated fat redistribution is associated with marked acceleration of lipid turnover.8th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., USA, 4–8 February 2001, Abstract 663.
70.
CarrA., SamarasK., ChisholmD.J., & CooperD.A.Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet1998; 352: 1881–1883.
71.
SnidermanA.D., CianfloneK., ArnerP., SummersL.K.M., & FraynK.N.The adipocyte, fatty acid trapping, and atherogenesis. Arteriosclerosis, Thrombosis and Vascular Biology1998; 18: 147–151.
RudichA., VanounouS., ReisenbergK., PoratM., TiroshA., Harman-BochmH.The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes2001; 50: 1425–1431.
74.
MurataH., HruzP.W., & MuecklerM.The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Journal of Biological Chemistry2000; 275: 20251–20254.
75.
StevensG.J., LankfordA.C., ChenM., & JessenB.Inhibition of adipocyte differentiation in HIV-1 protease inhibitors: potential mechanisms based on changes in gene expression. Antiviral Therapy2000; 5 (Suppl. 5): 26.
76.
DowellP., FlexnerC., KwiterichP.O., & LaneM.D.Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. Journal of Biological Chemistry2000; 275: 41325–41332.
77.
ZhangB., MacNaulK., SzalkowskiD., LiZ., BergerJ., MollerD.E.Inhibition of adipocyte differentiation by HIV protease inhibitors. Journal of Clinical Endocrinology & Metabolism1999; 84: 4274–4277.
78.
MiserezA.R., BarellaL., MullerP.Y., SchwietertM., ErbP., KlimkaitT.Hyperlipoproteinaemia in HIV patients is linked to sterol-regulatory element-binding protein (SREBP)-1c.8th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., USA, 4–8 February 2001, Abstract 500.
79.
FajasL., SchoonjansK., GelmanL., KimJ.B., NajibJ., MartinG.Regulation of peroxisome proliferator-activated receptor γ expression by Adipocyte Differentiation and Determination Factor 1/Sterol Regulatory Element Binding Protein 1: implications for adipocyte differentiation and metabolism. Molecular and Cellular Biology1999; 19: 5495–5503.
80.
FlierJ.S., & HollenbergA.N.ADD-1 provides new insight into the mechanisms of insulin action. Proceedings of the National Academy of Sciences, USA1999; 96: 14191–14192.
81.
OsborneT.F.Sterol Regulatory Element-binding Proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. Journal of Biological Chemistry2000; 275: 32379–32382.
82.
HegeleR.A.Molecular basis of partial lipodystrophy and prospects for therapy. Trends in Molecular Medicine2001; 7: 121–126.
83.
BirnbaumM.J.Dialogue between muscle and fat. Nature2001; 409: 672–673.
84.
AbelE.D., PeroniO., KimJ.K., KimY-B, BossO., HadroE.Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature2001; 409: 729–733.
MontagueC.T., PrinsJ.B., SandersL., ZhangJ., SewterC. P., DigbyJ.Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes1998; 47: 1384–1391.
87.
AdamsM., MontagueC.T., PrinsJ.B., HolderJ.C., SmithS.A., SandersL.Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. Journal of Clinical Investigation1997; 100: 3149–3153.
88.
DespresJ-P, MoorjaniS., LupienP.J., TremblayA., NadeauA., & BouchardC.Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis1990; 10: 497–511.
89.
PedersenS.B., JonlerM., & RichelsenB.Characterization of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue. Journal of Clinical Endocrinology & Metabolism1994; 78: 1354–1359.
90.
FabrisR., NisoliE., LombardiA.M., TonelloC., SerraR., GranzottoM.Preferential channeling of energy fuels toward fat rather than muscle during high free fatty acid availability in rats. Diabetes2001; 50: 601–608.
91.
BjorntorpP.The regulation of adipose tissue distribution in humans. International Journal of Obesity1996; 20: 291–302.
92.
RietschelP., HadiganC., CorcoranC., StanleyT., NeubauerG., GertnerJ.Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. Journal of Clinical Endocrinology & Metabolism2001; 86: 504–510.
93.
HadiganC., CorcoranC., PiecuchS., RodriguezW., & GrinspoonS.Hyperandrogenemia in human immunodeficiency virus-infected women with lipodystrophy syndrome. Journal of Clinical Endocrinology & Metabolism2000; 85: 3544–3550.
94.
AndreP., GroettrupM., KlenermanP., de GiuliR., BoothB.L.Jr., CerundoloV.An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proceedings of the National Academy of Sciences, USA1998; 95: 13120–13124.
95.
NguyenA.T., GagnonA., AngelJ.B., & SoriskyA.Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS2000; 14: 2467–2473.
96.
RiddleT.M., KuhelD.G., WoollettL.A., FichtenbaumC., & HuiD Y.HIV protease inhibitor therapy increases hepatic lipoprotein production via stabilisation of activated Sterol Regulatory Element-Binding Protein-1 (SREBP-1) in the nucleus.8th Conference on Retroviruses and Opportunistic Infections, 4–8 February 2001, Chicago, Ill., USA, Abstract 659.
NolteL.A., YarasheskiK.E., KawanakaK., & HolloszyJ.O.The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes2001; 50: 1397–1401.
99.
Himms-HagenJ., MelnykA., ZingarettiM.C., CeresiE., BarbatelliG., & CintiS.Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes. American Journal of Physiology-Cell Physiology2000; 279: C670–C681.
100.
Himms-HagenJ., & HarperM-EPhysiological role of UCP3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis. Experimental Biology and Medicine2001; 226: 78–84.
101.
NolanD., & MallalS.Getting to the HAART of insulin resistance. AIDS2001 [in press].
102.
KosmiskiL.A., KuritzkesD.R., LichtensteinK.A., GlueckD.H., GourleyP.J., StammE.R.Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS2001 [in press].
103.
ShevitzA.H., KnoxT.A., SpiegelmanD., RoubenoffR., GorbachS.L., & SkolnikP.R.Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS1999; 13: 1351–1357.
104.
HobbsG.A., KeilbaughS.A., RiefP.M., SimpsonM.V.Cellular targets of 3′-azido-3′-deoxythymidine: an early (non-delayed) effect on oxidative phosphorylation. Biochemical Pharmacology1995; 50: 381–390.
105.
BarileM., ValentiD., QuagliarelloE., & PassarellaS.Mitochondria as cell targets of AZT (zidovudine). General Pharmacology1998; 31: 531–538.
106.
MasiniA., ScottiC., CalligaroA., CazzaliniO., StivalaL.A., BianchiL.Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage. Journal of the Neurological Sciences1999; 166: 131–140.
107.
DasK., LewisR.Y., CombatsiarisT.P., LinY., ShapiroL., CharrionM.J.Predominant expression of the mitochondrial dicarboxylate carrier in white adipose tissue. Biochemical Journal1999; 344: 313–320.
108.
NolanD., JohnM., & MallalS.Effects of gender and race in the antiretroviral therapy associated lipodystrophy syndrome. Journal of HIV Therapy2001; 6: 32–36.
109.
VonkemanH.E., ten NapelC.H.H., & van Oeveren-DybiczA.M., VermesI.β3-adrenergic receptor polymorphism and the antiretroviral therapy-related lipodystrophy syndrome. AIDS2000; 14: 1463–1464.
110.
MaherB., AlfirevicA., VilarJ., WilkinsE., ParkB.K., & PirmohamedM.TNF-α promoter region polymorphisms in patients with HIV-1 associated lipodystrophy.XIIIth International AIDS Conference. Durban, South Africa, 2000, Abstract LB 113.
111.
HotamisligilG.S.The role of TNFα and TNF receptors in obesity and insulin resistance. Journal of Internal Medicine1999; 245: 621–625.
